Hostname: page-component-76c49bb84f-sz5hq Total loading time: 0 Render date: 2025-07-04T10:36:41.518Z Has data issue: false hasContentIssue false
  • English
  • Français

Pain Free Efficacy of Sumatriptan in the Early Treatment of Migraine

Published online by Cambridge University Press:  02 December 2014

Susan E. Jelinski ,
Werner J. Becker ,
Suzanne N. Christie ,
Faiz F. Ahmad ,
William Pryse-Phillips  and
Scott D. Simpson
Susan E. Jelinski
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
Werner J. Becker*
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
Suzanne N. Christie
Affiliation:
Department of Radiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke University, Sherbrooke, QC, Canada
Faiz F. Ahmad
Affiliation:
GlaxoSmithKline, Mississauga, ON, Canada
William Pryse-Phillips
Affiliation:
GlaxoSmithKline, Mississauga, ON, Canada Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada
Scott D. Simpson
Affiliation:
GlaxoSmithKline, Mississauga, ON, Canada
*
Department of Clinical Neurosciences, Foothills Medical Centre, 12th Floor, Neurology, 1403-29th Street NW, Calgary, Alberta, T2N 2T9, Canada
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

There is evidence that headache response rates may be higher if triptans are used early when a migraine attack is still mild, as compared to when it is treated after pain has reached moderate or severe intensity.

Methods:

In this randomized, double blind, placebo controlled, parallel group clinical trial, 361 patients took either placebo, sumatriptan 50 mg, or sumatriptan 100 mg in a single attack study. The primary outcome measure was pain-free status at two hours.

Results:

In the intention to treat group, two hour pain free rates were 16%, 40%, and 50% in the placebo group, sumatriptan 50 mg group, and the sumatriptan 100 mg group respectively (p<0.001, active treatment groups vs. placebo).

Conclusions:

Both sumatriptan 50 mg and 100 mg were significantly superior to placebo for the pain-free end point at two hours. The pain-free response rates in this trial where sumatriptan was taken while the headache was still mild were generally higher than in older clinical trials where headache was treated after reaching a moderate or severe intensity.

Résumé

RÉSUMÉ Contexte:

Le taux de réponse serait plus élevé si les triptans sont utilisés tôt au cours d’une crise de migraine alors que les symptômes sont légers plutôt que quand la douleur est devenue modérée ou sévère.

Méthodes:

Il s’agit d’une étude de pharmacologie clinique randomisée, à double insu, avec placebo et groupes parallèles. 361 patients ont pris soit le placebo, le sumatriptan 50 mg ou le sumatriptan 100 mg au cours d’une seule crise migraineuse. Le critère d’évaluation primaire était l’absence de douleur 2 heures après la prise du médicament.

Résultats:

À l’analyse selon l’intention de traitement, le taux de patients sans douleur était de 16%, 40% et 50% pour le groupe placebo, le groupe sumatriptan 50 mg et le groupe sumatriptan 100 mg respectivement (groupes traitement actif versus placebo, p ˃ 0,001).

Conclusions:

Le sumatriptan 50 mg et 100 mg étaient significativement supérieurs au placebo quant au critère d’évaluation primaire, soit l’absence de douleur 2 heures après la prise du médicament. Le taux de réponse, soit l’absence de douleur, dans cette étude où le sumatriptan était pris alors que la céphalée était encore légère, était généralement plus élevé que dans d’autres essais cliniques où la céphalée était traitée alors qu’elle était modérée ou sévère.

Information

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 33 , Issue 1 , February 2006 , pp. 73 - 79
Copyright
Copyright © The Canadian Journal of Neurological 2006

References

1. O’Brien, B, Goeree, R, Streiner, D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol. 1994; 23:1020–6.Google Scholar
2. Gibbs, TS, Fleischer, AB Jr., Feldman, SR, et al. Health careutilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache. 2003; 43:330–5.CrossRefGoogle Scholar
3. Lipton, RB, Scher, AI, Kolodner, K, et al. Migraine in the UnitedStates: epidemiology and patterns of health care use. Neurology. 2002; 58:885–94.CrossRefGoogle Scholar
4. Gerth, WC, Carides, GW, Dasbach, EJ, et al. The multinational impactof migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics. 2001; 19:197–206.CrossRefGoogle Scholar
5. Fishman, P, Black, L. Indirect costs of migraine in a managed carepopulation. Cephalalgia. 1999; 19:50–7.Google Scholar
6. Von Korff, M, Stewart, WF, Simon, DJ, Lipton, RB. Migraine andreduced work performance: a population-based diary study. Neurology. 1998; 50:1741–5.Google Scholar
7. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991; 325:316–21.Google Scholar
8. Visser, WH, Ferrari, MD, Bayliss, EM, et al. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. Cephalalgia. 1992; 12:308–13.Google Scholar
9. Nappi, G, Sicuteri, F, Byrne, M, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994; 241:138–44.Google Scholar
10. Cutler, N, Mushet, GR, Davis, R, et al. Oral sumatriptan for the acutetreatment of migraine: evaluation of three dosage strengths. Neurology. 1995; 45:S5–9.Google Scholar
11. Sargent, J, Kirchner, JR, Davis, R, Kirkhart, B. Oral sumatriptan iseffective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995; 45:S10–14.Google Scholar
12. Burstein, R, Yamamura, H, Malick, A, Strassman, AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998; 79:964–82.Google Scholar
13. Cady, RK, Sheftell, F, Lipton, RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000; 22:1035–48.Google Scholar
14. Winner, P, Mannix, LK, Putnam, DG, et al. Pain-free results withsumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003; 78:1214–22.Google Scholar
15. Scholpp, J, Schellenberg, R, Moeckesch, B, Banik, N. Early treatment of a migraine attack while pain is still mild increases the efficacyof sumatriptan. Cephalalgia. 2004; 24:925–33.Google Scholar
16. Klapper, J, Lucas, C, Rosjo, O, Charlesworth, B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004; 24:918–24.Google Scholar
17. Mathew, NT, Kailasam, J, Meadors, L. Early treatment of migrainewith rizatriptan: a placebo-controlled study. Headache. 2004; 44:669–73.Google Scholar
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8 Suppl 7:1–96.Google Scholar
19. Kosinski, M, Bayliss, MS, Bjorner, JB, et al. A six-item short-formsurvey for measuring headache impact: the HIT-6. Qual Life Res. 2003; 12:963–74.Google Scholar
20. Goadsby, PJ. Serotonin 5-HT receptor agonists in migraine. CNSDrugs. 1998; 10:271–86.Google Scholar
21. Ferrari, MD, Roon, KI, Lipton, RB, Goadsby, PJ. Oral triptans(serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358:1668–75.Google Scholar
22. Burstein, R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001; 89:107–10.Google Scholar
23. Burstein, R, Collins, B, Jakubowski, M. Defeating migraine pain withtriptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004; 55:19–26.Google Scholar
24. Sramek, JJ, Hussey, EK, Blements, B, Cutler, NR. Oral sumatriptanpharmacokinetics in the migraine state. Clin Drug Invest. 1999; 17:137–44.Google Scholar
25. Nett, R, Landy, S, Shackelford, S, et al. Pain-free efficacy aftertreatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003; 102:835–42.Google Scholar
26. Belsey, J. Reconciling effectiveness and tolerability in oral triptantherapy: a quantitative approach to decision making in migraine management. J Clin Res. 2001; 4:105–25.Google Scholar
27. Amanzio, M, Benedetti, F. Neuropharmacological dissection ofplacebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999; 19:484–94.Google Scholar
28. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 Suppl 1:9–160.Google Scholar